Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 45035 results
Abbvie to develop and commercialize Infinity's cancer drug duvelisib
By PBR Staff Writer
Infinity Pharmaceuticals has entered into a global collaboration with AbbVie to develop and commercialize duvelisib (IPI-145), its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, to treat patients with cancer.
Contract Research & Services > Contract Services > News
Halozyme gets fast track status for PEGPH20 program in metastatic pancreatic cancer
By PBR Staff Writer
Halozyme Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its program investigating PEGPH20 in combination with gemcitabine and nab-paclitaxel to treat patients with metastatic pancreatic cancer.
Regulatory Affairs > News
Alimera's ILUVIEN secures Swedish marketing authorization to treat chronic DME
By PBR Staff Writer
Alimera Sciences has received marketing authorization from the Swedish Medical Products Agency for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME).
Drug Research > Drug Delivery > News
CMC Biologics, Zymeworks partner for bi-specific antibody product candidate
By PBR Staff Writer
CMC Biologics and Zymeworks, a Canadian biotherapeutics firm, have entered into a master services agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody.
Drug Research > Drug Discovery & Development > News
Concordia to acquire US and Puerto Rican rights of Zonegran from Eisai
By PBR Staff Writer
Concordia Pharmaceuticals, a subsidiary of Concordia Healthcare, has agreed to buy Eisai's Zonegran for commercialization and distribution in the US and Puerto Rico.
Contract Research & Services > Contract Services > News
Diplomat to distribute SYNRIBO for Injection
Diplomat, the nation's largest independent specialty pharmacy, announced that it will be the exclusive distributor for SYNRIBO (omacetaxine mepesuccinate) for subcutaneous injection intended for home use.
Contract Research & Services > Contract Services > News
ViiV Healthcare's HIV drug Triumeq gets marketing authorisation in Europe
By PBR Staff Writer
The European Commission (EC) has granted marketing authorization for UK-based ViiV Healthcare's Triumeq tablets to treat HIV in adults and adolescents aged 12 years and older and weighing at least 40kg.
Regulatory Affairs > News
Alkermes completes patient enrollment in Phase II ALKS 3831 trial to treat schizophrenia
By PBR Staff Writer
Alkermes has completed patient enrollment in a double-blind, active-controlled, dose-ranging Phase II trial of ALKS 3831, an investigational, novel, oral, broad-spectrum atypical antipsychotic medicine, to treat schizophrenia.
Contract Research & Services > Clinical Trials > News
Knight Therapeutics acquires Orphan Canada
Knight Therapeutics, a leading Canadian specialty pharmaceutical company, has entered into an asset purchase agreement with Orphan Canada (Orphan) related to the Canadian rights for ATryn and PHOTOFRIN (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions.
Contract Research & Services > Contract Services > News
Lundbeck launches Northera to treat neurogenic orthostatic hypotension in US
By PBR Staff Writer
Danish global pharmaceutical firm Lundbeck through its US subsidiary has launched Northera (droxidopa) capsules for the treatment of neurogenic orthostatic hypotension (NOH).
Production & Manufacturing > Manufacturing > News
EMD Serono, MGH partner to advance lupus research
By PBR Staff Writer
Merck subsidiary EMD Serono Research and Development Institute has entered into a collaborative research agreement with Massachusetts General Hospital (MGH) for Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) pathogenesis.
Contract Research & Services > Contract Research > News
Macrocure closes patient enrolment in Phase III CureXcell trial to treat diabetic foot ulcers
By PBR Staff Writer
Israel-based biotechnology firm Macrocure has completed patient enrollment in its double-blind, Phase III clinical trial of CureXcell to treat diabetic foot ulcers (DFUs).
Contract Research & Services > Clinical Trials > News
BioLegend acquires Covance's antibody products business unit
BioLegend has acquired the shares of Covance Antibody Services, a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014.
Production & Manufacturing > Manufacturing > News
Chimerix and BARDA continu partnership in development of Brincidofovir for smallpox
Chimerix, a biopharmaceutical company developing novel, oral antivirals, has announced an award of $17m through the extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of its broad spectrum antiviral brincidofovir (BCV, CMX001) as a medical countermeasure to treat smallpox.
Drug Research > Drug Discovery & Development > News
Over the counter pain reliever may restore immune function in old age
New research involving mice suggests that the key to more youthful immune function might already be in your medicine cabinet. In a report published in the Journal of Leukocyte Biology scientists show that macrophages from the lungs of old mice had different responses to Mycobacterium tuberculosis than macrophages from young mice, but these changes were reversed by ibuprofen.
Production & Manufacturing > OTC > News
136-150 of 45035 results